HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC

Yu, HA; Yang, JCH; Hayashi, H; Goto, Y; Felip, E; Reck, M; Vigliotti, M; Dong, Q; Cantero, F; Fan, PD; Kanai, M; Sternberg, DW; Jaenne, PA

Yu, HA (通讯作者),Mem Sloan Kettering Canc Ctr, Dept Med, Med Oncol, New York, NY 10065 USA.

FUTURE ONCOLOGY, 2023; 19 (19): 1319